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Background
Forklead Box Protein 3 (FoxP3) is a gene that controls the development and function ofr-
regulatory (Treg) cells. Dysfunction ofTreg cells can trigger an autoimmune condition caused
by a change in FoxP3 promoter gene activity. Aim of this study is to correlate between FoXp3
T-regulator promoter gene polymorphisms in patients with Graves' disease in west Sumater4
Indonesia.
Method
This study was an obsewational study with cross sectional comparative study design.
consecutive sampling was conducted in patients with Graves' disease who came to outpatiint
clinic and treated in Dr. M. Djamil Hospital, Padang. Blood sampling was performed on 30
Graves' subjects and 30 healthy control subjects based on inclusion and exclusion criteria. DNA
isolation, primary construction, polymorphism identification were analysed by pcR method.
Results
Results ofthis study obtained the most age ofpatients with Graves' disease is 30-40 years with
female gender. Graves' patient group was found to have SNp rs2232365, SNp rs376i547, sNp
rs3761548 and sNP rs3761549 with mutant heterozygote polymorphisms were mostly found,
and there was no polymorphism of SNP rs2232364 found in patients with Graves, diiease on
this study. we also found deletion in sNP FOXP3 which haven't been noted in NCBI which
located in base 49, as seen in Figure 3.There was no correlation between polymorphisms of
promotor gene FOXP3 in Graves' disease group and healthy control group.
Conclusion
This study proves that there are polymorphisms of promoter gene FoXp3 in patients with
Graves' disease, however there is no correlation between polymorphisms FoXp3 promoter
gene in Graves' disease compare to control.
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INTRODI]CTION
Graves' disease (GD) is an autoimmune thyroid disease caused by overexpressed
autoantibodies resulting in hyperthyroidism, goiter, ophtalmopathy and or dermatopithy (r).
Graves' disease thought to be a T-helper 2 (Th2)-cell driven mediated disease that stimulates
production of autoantibodies @). Dysfunction of regulatory T cells (Tregs) in maintaining
balance between T-helper 1 (Th1) and r-helper 2 (TM) is one of the factors that may cause the
occurence of autoimmune, especially Graves' disease (3).
Regulatory T cells have been recognized as cD4 T cells that plays a role in maintaining
balance between peripheral tolerance and preventing autoimmune disease (a). one ofthe best
characterized marker of Tregs is the forkhead box protein-3 (Foxp3) which the only one
marker that located in intracellular ofrregs cells. FoXp3 gene located on position Xpl 1.23 in
the short arm ofX chromosome, consist of promoter region and conserved non-coding DNA
sequence (CNS1-3) (5). Promoter region of FO)G3 is responsible in maintaining differentiation
ofregulatory T cells in peripheral. Functional mutations in FoXp3 gene promoter have been
associated with various autoimmune disease such as psoriasis, SLE, and rhinitis allergy (o).
There are five variants in the promotor region FoXp3 (-924 NG (rs2232365), - l3s3c/T(rs2232364), 
-2383clT (n3761549), - 3279clA (rs3761548) and - 3 499NG (rs3761s47))have
been associated with altered function of FoxP3 which may lead to Tregs dysfunctiol tii
Aim of this study was to identifo the role of Fo)G3 gene promoter in association with
susceptibility to GD in west Sumatra, Indonesia. This is the first study in population of
Indonesia, especially west Sumatra showing association between role of h{ixp3 gene
promoter and Graves' disease.
METHODS
This was a case-control study, which compared patients diagnosed as craves' disease
based on clinical and laboratory examination and healthy subjectsis control. Subjects were
recruited at outpatient clinic of Metabolism and Endocrinology division, Department of
Intemal Medicine, M. Djamil Hospital, padang, West Sumatm, Indonesia.
As much as 30 subjects with Graves' disease and 30 healthy subjects were recruited as subjects
ofthis study. Diagnosis ofGD were based on clinical symptom and occurrence ofautoantibody
thyroid, TRAb. This study has been approved by Research Ethical commiftee ofFaculty of
Medicine, Andalas University (No. 3 I 6/KEp,GK/20 I 7).
Age, gender, thyroid antibody (TRAb) were noted as characteristic data ofthis study.
New venous blood sample were taken for measurement of serum FT4, TSH, TRAb and gene
polymorphisms. TRAb were measured using a receptor assay, Human TRAb Elisa kit b6T,
Bioassay Tech. Lab (TRAb > 1,0 IU,{- being considered as TRAb positive).
Genomic DNA was extracted from EDTA-anticoagulated blood with standard phenol-
chloroform method. Five sNps of gene promoter Foxp3, -g24NG (rs2232365), - l jg3c/T(rs2232364), - 2383clr (rs3761549), - 3279c/A (rs3761548) and - 3499NG (rs3i61547), was
perfiormed using PCR direct DNA method. primer sequences used were: FoXp3-F i (5,-
ATGCATGTGTCCATTTCTCTC-3'); FOxp3-Rl (s,- TTTCATATCGGGGTCTGGCATC-3'); FOXP3-F2 (5'-CCTGGATTCTCACACTCATCTC-3,) and Foxp3-R2 (5'-
GAAGGACCGAGCTGACATTAC.3' ).
Data were analyzed using SPSS version 20.0. The distribution of genotypes in both
groups was compared using the chi-squared test. Data were expressed as mean * SD with level
of significance set at p<0,05-
RESULTS
Baseline characteristic of patients and control
Thirty GD patients and healthy control subjects were enrolled in this study. Most GD
patients were female (76,70/o), therefore to maintain uniformity 76,70/o healthy control were
also female. Mean of age ofthis study were 40,23 + 9,98 years old, with age tetween 3l-40
was the most common age found in this study. As shown in taUte l, the levJls of TRAb were
significantly higher in GD patients compared to control.
Table 1. Baseline charaqteristics of Graves' patients and control
Characteristic Graves'patients Control
n (3q)
Gender
Male
Female
Age (years old),
Mean + SD
2t*30
31-40
41-50
51-60
TRAb (pelml-)
Mean t SD
40,23 + g,gg
5
1t
8
6
288,25!267,6
23,3 7
76,7 23
39,6 + 9,76
16,7 736,7 g
26,7 g
206
- 144,21!2t,13
23,3
76,7
7
23 1,00
0,805
23,3
30
26,7
20
0.000
Prevalence of FOXP3 polymorphisms in GD pafients
Aim of this study is to prove the existence of FOXP3 gene promoter polymorphism inpatients with Graves'disease. The sequence examination on the FOXP3 gene produces 5 SNp
found on the FoxP3 gene promoter. In 30 subjects with GD, all subjects nlaa mutations (100%)
with each having 1,2 or 3 mutations with different SNPs whili 26 control subjects had
mutations (86.7%) with different SNps.
Polymorphism of sNP -924AlG and -1383C/T in GD patients
Table 2 shows lhat lhere is no polymorphism in Stw rs2232364 which is indicated bythe finding of CC a]lel_e (wild Epe) in both patient and control group. polymorphism Sxp924NG was higher in Graves' patients with a percentage of 61.1% versus 3g.9o/oin the control
g_.9up, with heterozygous mutations (AG) being the most common. From the results ofthe SNp
-924NG statistical test, there was no difference between the Graves patient group and the
control (p> 0.05).
Table 2' PolvmoPhisms of SNP 924AlG and 1383C/T in GD patients and control
Allele Frequency
Allete Graves'patlentsSNP Control Total
%%%
rs2232365
(e24 AtG)
rs2232364
(r383 C/T)
100
100
100
100
0
0
23
18
l6
57
0
0
12
7
8
27
0
0
11
ll
8
30
0
0
AA
AG
GG
CC
CT
TT
47,8
6l,l
50
52,6
0
0
5))
38,9
s0
47,4
0
0
0,679
Cannot be
analyzed
p
Deletion in FOXP3 Gene Promotor Sequence
On this study, we are also found that there is deletion found ofnew SNps which not yet
registered in GeneBank NCBI located on base 49,259,740 marked with red box. This deletion
was found in only 3 samples ofGraves' patient group, and was not found in the control group.
In this SNP, a basic change occurs which is supposed to be a T allele, being lost on samples
C15, C16 and C l7 as shown in figure l. These samples were female, in which two of the three
samples had higher TRAb levels than mean of rRAb in GD patients with rRAb level of 964 ,14
ng/ml and 816,26 nglml compared to 288,25 tZ67 n/ml.
!!. .. . 
-
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Figure l. Deletion of 3 Graves'disease patient; (Cli, C16 and CIZ)
Polymorphism of Sl{P - 2383C/T, - 3279ClA and - J499A/G in GD parients
From this study, it is seen that these three sNps had polymorphisms characterized by
the discovery ofhomozygous and heterozygous polymorphism/mutants. Table 3 shows that in
Graves' patients with SNP polymorphism 3499 A/G has the highest percentage in heterozygous
mutant polymorphism (AC). There was no statistically significant difference between the three
groups (p> 0.05). Polymorphism sNP 3279 clA heterozygore mutant (AC) has the highest
percentage. statistically, there was no significant difference (p> 0,05). Furthermore, in sNp
rs3761549 the percentage of heterozygous mutants (cr) is higher than other polymorphism
motifs. From the results of statistical tests conducted, there is no significant differenie (p>
0.0s).
Table 3. Polymophisms of SNP - 2383C1T, - 3279ClA and - 3499A/G in GD patients
and control.
Allele Frequencv
sNP Allele Graves', Control Totalpauents
t%f%f%
rs3761547 AA* 22 51,2 21 48,8 43 100
(3499 AIG) AG 6 66,7 3 33,3 9 100 0,586GG2403605100
rs3761548 AA* 4 40 6 60 l0 100
(3279 CIA) AC 8 72,7 3 27,3 1l 100 0,293
cc 18 50 18 50 36 100
rs3761549 CC* 22 52,4 23 47,6 45 100
(2383 C/T) CT 6 60 4 40 10 100 0,764
TT2403605100
* : wild ype
Association between FOXP3 polymorphisms and GD
The result of complete analysis of polymorphism of SNP FOXP3 gene promoter with
incidence of Graves' disease can be seen in table 4 Table 4 shows that based on PCR direct-
sequencing-method result in Graves' patients found SNP 924 A/G polymorphism more
common in the Graves' than controls, with a percentage of 54.3o/oversus 45.7o/o,but statistical
tests showed no difference between both groups with p> 0.05. The polymorphism of SNP 3499
A/G, SNP 3279 CIA and SNP 2383 CIT were found to be similar between GD group and
controls with 50% in percentage, no significant differences were found between the two
groups. Based on Table 5.6, it was seen in the Graves group of patients with SNP 924 NG
polymorphism and 3279 C/A higher than those without polymorphism and no SNP
polymorphism 1383 C/T found on this study.
Table 4.Polymomhisms entsSNP Graves'disease
potu*omrri.*, ffi Total p
rs223236i
Presence 19 54,3 16 45,7 35 100 
^ .Absence I I 44 14 5O 25 100 u,6
r9232364
Presence000000
Absence 30 50 30 50 60 100
rs3761547
Presence 8 50 8 50 16 100Absence 22 50 22 50 44 100 l'uu
rs3761548
Presence 26 50 26 50 52 100Absence 4 50 4 50 8 100 l'Ou
rs3761549
Presence 8 50 8 50 16 100Absence 22 50 22 50 44 t00 l'uu
p
DISCUSSION
characteristics ofstudy subjects in the form ofsex and age did not differ significantly
between the GD and control group. In this study, the age range between 3 1-40 years ind female
gender was the age and sex group which mostly found in GD patients. This ii consistent with
the American Thyroid Association's data which explains thai although Graves'disease can
occur in all age groups, it is more common in women than in men with a 7-g: I ratio. Like most
other autoimmune diseases, female sex is the most fiequent group of autoimmune diseases. It
is suspected that the role of estrogen in stimulating antibody production and autoantibodies
through B cells. Estrogen also increases the levels of IL-4,-IL-10 and rGF-p as well as
expression of cD80 and FOXP3, which further increases crLA-4 activity and r-reg cell
Populations (8).
The Fo)G3 gene is located on chromosome Xp1 1.23 with a length of 1,146 bp,
containing I 1 exons coding 431 amino acids. The FoXp3 gene is the main gene that
responsible for development of regulatory T cells, which co*prise the promoter relion, first
intron (consisting of cNSl and cNS2), and intron after the first exon coding lcris:;. rneFOXP3 promoter region is the area most responsible for T-regulator cell *rliiTerentiation.
Mutations in the FoXP3 gene promoter region may lead to the dysfunction and formation of
auto aggressive lymphocyte clones that contribute to the occunence of autoimmunity. In the
FOXP3 gene promoter region there are 5 SNps that may affect the expression of the Foxp3gene,ie-924Alc(rs2232365),-1383C/T(rs2232364),-34ggA/c(rs3761547),_3Z7gC
/ A (rs3761548) and - 2383c /T (rs3761549). of all the FoXp3 mutatiom thut tigg.,
autoimmunity, manifestations of the thyroid gland are the most frequently nffsdgd rs,ro).
ie-9244lG(rs223236s),-3499AlG(rs3761s47t,-3279i/AGs3761sa\ind-)l$ctt
(rs3761549) found in GD. The polymorphism of SNp rs376154g and,rs2232365 were the mosr
common SNPs in this study in which of26 subjects experienced polymorphism SNp rs376154g
wilh the finding of heterozygous mutants (AC) of lz.7% and homozygotes (cc) of 50% SNp
rs3761548. while SNP rs2232365 of l9 subjects found heterozygous mutant polymorphism(AG) of6l.l% and homozygous mutants by 50o/o. From the staiiitical test results, there was
no significant difference between the two SNps with the control group with p> 0.05.
Polymorphism SNP rs3761547 andrs376l549 were found tobe26.l%Jof ihe 30 sijects ofGraves' patients. In this study, no SNp rs2232364 polymolphism was found in both'Graves
and control groups. In this study, we also found 1 new SNp that experienced deletion in 3
samples ofGraves' patients. The deletions in the 49,259,740-base ordei found are not listed on
the Gene Bank NCBI. The three samples were female sex, of which two of the three samples
had higher TRAb levels than the mean Graves'average ofg90 20 ng/ml.
- .owe1 et al study in 2006, conducted 633 Graves' patienti in the united Kingdom
showed no finding of polymorphism of SNp rs2232365 and rs3761549 gene promoters", but
there is a polymorphism in the GATTC minor haplotype suspected of con-tribuiing to Graves'
disease. Inoue et al in 2010 resarch conducted in lapan showed similar results witf, this study,
where sNP polymorphism rs3761548 was also found in Graves patients with the most
9911nonly found cc genotype of 7l%, followed by an AC genotype of 17.7o/o (lnow et al.,2010). In addition to SNP rs3761548, Inoue et al, also examined two other SNps namely SNP
rs3761547 and rs3761549. However, unlike this study, sNp polymorphism rs376l5i7 was
fbund as much as 43.1o/o and, SNp rs3761549 as rnuch as 3l.e%-greair than polymorphism
found in this study that is 26.70/o. yu et al in 2017 who conducGd a study oi 514 ciaves,
populations in china showed the acquisition ofSNp polymorphism rs376154g and rs3761549
with 
.percentages respectively of 93%o and 43o/o, gre;te; than this study of g6.7% and 26.7vo{ I I.l2.1l r
In this study, no diflerence was found between polymorphism of SNp FO)G3 gene
promoter in patients with Graves'disease with control with p> 0.05 on each SNp. This is
consistent with the study of owen et al in 2008 in the united Kingdom population showing
that there is no difference in the relationship between FOXP3 gene polymorphisms and healthy
controls, while difrerent results are shown by the study of zheng et aI.,2015 which examines
Graves' populations in Han chinese populations which shows there is a difference between
SNP polymorphism rs3761548 and healthy control (14,15).
Many factors affect the incidence of Graves' disease, both other genetic and
environmental factors. The study of Eliana et al., 2017 shows the presence of CrLA4 gene
polymorphs of49 codons 17 exon I in Graves patients between relapse and non-relapse patints.
Cytotoxic TJymphocyte-associated Protein-4 (CTLA4) is one ofthe markers on the suiface of
T-regulator cells that also play a role in immune homeostasis along with the FoXp3 gene
present in intracellular T-regulators. Recent research also shows that environmental factors can
also. interact with certain genes that lead to susceptibility to Graves' disease through epigenetrc
modulation, such as the occurrence ofhistone modification. Research ofyan et al_ 201ifound
that histone H4 acetylation levels decreased in Graves patients, while Histone deacetylase 1(HDACI) and Histone deacetylase 2 (trDAC2) levels were very high which showed that
histone modification or modification occurred in Graves patients. Horiever, the study of the
role of histone modification in Graves 'own disease is still largely unrelated to the iistone-
modifring gene of sirtuinl (SIRTI) suspected of having an effect on histone modification in
Graves' patients. From some research that has been done on Fo)G3 polymorphism, SNp
*2232365 also found in some other autoimmune diseases such as chron dir.uri, Addi.or',
disease and psoriasis. while sNP rs3761548 is also found in allergic rhinitis, atopy, psoriasis
and systemic lupus erythematosus. The discovery of this FoXp3 gene polymorpirism in a
number of other autoimmune diseases suggests that the FoXp3 gene piays a roie in maintaining
immune system balance and controlling T cell activity and effeitor i ."11 1'*.1ion tre.r,rsr
CONCLUSION
In conclusion, we prove that there are polymorphisms of FoXp3 gene promoter SNp -
924NG, -2383c1r, - 3279clAand - 3499dG and no polymorphism sNp - t 3it3c/t found onthis study. Furthermore, subjects carrying SNP -g24NG and -3279ClA FoXp3
polymorphisms are more susceptible to GD which mostly found on GD patients.
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